(Q53245216)

English

Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.

scientific article published in January 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

0 references

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

Maria Luisa Brandi

4

object named as

Maria L Brandi

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

author name string

David M Reid

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

David Hosking

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

John D Wark

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

Georges Weryha

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

João F Marques-Neto

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

Keavy A Gaines

8

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

Nadia Verbruggen

9

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

Mary E Melton

10

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

Clinical Drug Investigation

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

26

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

63-74

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surrogates for fracture endpoints in clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How useful are measures of BMD and bone turnover?

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A method to assess the proportion of treatment effect explained by a surrogate endpoint

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bisphosphonates in osteoporosis: recent clinical experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comprehensive review of treatments for postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Importance of precision in bone density measurements

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Uncertain future of trials in osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17163237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00044011-200626020-00002

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17163237

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53245216&oldid=1551622273"